title: Latent Kaposi's sarcoma-associated herpesvirus infection in bladder cancer cells promotes drug resistance by reducing reactive oxygen species.
abstract: Kaposi's sarcoma-associated herpesvirus (KSHV) is the major etiologic agent of Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease. Recent studies have indicated that KSHV can be detected at high frequency in patient-derived bladder cancer tissue and might be associated with the pathogenesis of bladder cancer. Bladder cancer is the second most common cancer of the genitourinary tract, and it has a high rate of recurrence. Because drug resistance is closely related to chemotherapy failure and cancer recurrence, we investigated whether KSHV infection is associated with drug resistance of bladder cancer cells. Some KSHV-infected bladder cancer cell lines showed resistance to an anti-cancer drug, cisplatin, possibly as a result of down-regulation of reactive oxygen species. Additionally, drug resistance acquired from KSHV infection could partly be overcome by HDAC1 inhibitors. Taken together, the data suggest the possible role of KSHV in chemo-resistant bladder cancer, and indicate the therapeutic potential of HDAC1 inhibitors in drug-resistant bladder cancers associated with KSHV infection.
authors: Department of Microbiology and Immunology, Eulji University School of Medicine, Daejeon, 34824, Republic of Korea.
authors: Suhyuk
authors: S
authors: Lee
authors: Department of Microbiology and Immunology, Eulji University School of Medicine, Daejeon, 34824, Republic of Korea.
authors: Jaehyuk
authors: J
authors: Jang
authors: Department of Microbiology and Immunology, Eulji University School of Medicine, Daejeon, 34824, Republic of Korea.
authors: Hyungtaek
authors: H
authors: Jeon
authors: Department of Microbiology and Immunology, Eulji University School of Medicine, Daejeon, 34824, Republic of Korea.
authors: Jisu
authors: J
authors: Lee
authors: Department of Microbiology and Immunology, Eulji University School of Medicine, Daejeon, 34824, Republic of Korea.
authors: Seung-Min
authors: SM
authors: Yoo
authors: Department of Urology, Eulji University Hospital, Eulji University School of Medicine, Daejeon, 34824, Republic of Korea.
authors: Jinsung
authors: J
authors: Park
authors: Department of Microbiology and Immunology, Eulji University School of Medicine, Daejeon, 34824, Republic of Korea. imslee@gmail.com.
authors: Myung-Shin
authors: MS
authors: Lee
mesh_terms: D045744:Cell Line, Tumor; D002945:Cisplatin / Q000494:pharmacology; D015536:Down-Regulation; D019008:Drug Resistance, Neoplasm; D006566:Herpesviridae Infections / Q000378:metabolism / Q000821:virology; D019288:Herpesvirus 8, Human / Q000235:genetics / Q000502:physiology*; D056284:Histone Deacetylase 1; D056572:Histone Deacetylase Inhibitors / Q000494:pharmacology; D006801:Humans; D040081:Protein Array Analysis; D017382:Reactive Oxygen Species / Q000378:metabolism; D012514:Sarcoma, Kaposi / Q000150:complications / Q000821:virology*; D001749:Urinary Bladder Neoplasms / Q000821:virology*
chemical_list: D056572:Histone Deacetylase Inhibitors; D017382:Reactive Oxygen Species; C110550:HDAC1 protein, human; D056284:Histone Deacetylase 1; D002945:Cisplatin
keywords: HDAC1; KSHV; bladder cancer; cisplatin; reactive oxygen species